Literature DB >> 17502787

Treatment-resistant depression: response to low-dose transdermal but not oral selegiline.

Peter T Morgan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17502787     DOI： 10.1097/01.jcp.0000270085.15253.15

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  2 in total

1.  Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report.

Authors:  Yuji Kitaichi; Takeshi Inoue; Nobuyuki Mitsui; Shin Nakagawa; Rie Kameyama; Yoshiyuki Hayashishita; Tohru Shiga; Ichiro Kusumi; Tsukasa Koyama
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-17       Impact factor: 2.570

Review 2.  EMSAM (deprenyl patch): how a promising antidepressant was underutilized.

Authors:  Gregory M Asnis; Margaret A Henderson
Journal:  Neuropsychiatr Dis Treat       Date:  2014-10-06       Impact factor: 2.570
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.